Tesavel

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
19-09-2023
Karakteristik produk Karakteristik produk (SPC)
19-09-2023

Bahan aktif:

sitagliptin

Tersedia dari:

Merck Sharp & Dohme B.V.

Kode ATC:

A10BH01

INN (Nama Internasional):

sitagliptin

Kelompok Terapi:

Drugs used in diabetes

Area terapi:

Diabetes Mellitus, Type 2

Indikasi Terapi:

For patients with type-2 diabetes mellitus, Tesavel is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a PPARγ agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination witha sulphonylurea and metformin when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control;a peroxisome-proliferator-activated-receptor-gamma (PPARγ) agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these agents do not provide adequate glycaemic control.Tesavel is also indicated as add on to insulin (with or without metformin) when diet and exercise plus stable dosage of insulin do not provide adequate glycaemic control.

Ringkasan produk:

Revision: 28

Status otorisasi:

Authorised

Tanggal Otorisasi:

2008-01-10

Selebaran informasi

                                32
B.
PACKAGE LEAFLET
33
PACKAGE LEAFLET: INFORM
ATION
FOR THE PATIENT
TESAVEL 25 MG FILM-
COATED TABLETS
TESAVEL 50 MG FILM-COATED TABLETS
TESAVEL 100 MG FILM-COATED TABLETS
sitagliptin
READ ALL OF THIS LEAFLET CAREFULLY B
EFORE YOU START TA
KING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU
.
-
Keep this leaflet. You may
need to read it again.
-
If you have
any further
questions, ask your doct
or, pharmacist, or nurse.
-
This medicine has been prescribed for you
only. Do not pass it
on to others. It may
harm them,
e
ven if their s
igns of illness
are the same as yours.
-
If you get
any side effects
, tal
k to your doc
tor, pharma
cist, or nurse. This incl
udes any possible
side effects
not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
1.
What Tesavel is an
d what it is used for
2.
What you need to know b
efore you take
Tesavel
3.
How to take
Tesavel
4.
Possible
side effects
5.
How to store
Tesavel
6.
Contents of the pack and other
information
1.
WHAT TESAVEL IS AND WHAT IT IS USED FOR
Tesavel contains the
active substance sitagliptin which
is a member of a class of med
i
cines called
DPP-4 in
hibitors (dip
eptidyl peptidase-
4 inhibitors) that
lowers bl
ood sugar level
s in adult patients
with type 2 diabetes mellitus
.
This medicine helps to increase the levels of insulin produced
after a meal and decreases the amount
of sugar
made by the body.
Y
our doctor ha
s prescribed
this medicine
to help lower your
blood sugar, wh
ich is too high
because of
your type
2 diabetes.
This medicine
can be used alone or i
n combinati
on with certain other medicines
(insulin, metformin, sulphonylur
e
as, or glitazones) th
at lower bloo
d suga
r, which you may already be
taking for y
our diabetes to
gether with a fo
od and exercise plan.
What is type 2 diabetes?
Type
2 diabetes is a
condition i
n which your body does not make enough insulin, and the insulin
that
your body produce
s does not wo
rk as
well as it should. Your body c
an also ma
ke too much sug
ar.
When this ha
ppens, sugar (glucose
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Tesavel 25 mg film-
coated tablet
s
Tesavel 50 mg film-
coated tablet
s
Tesavel 100 mg film-
coated tablet
s
2.
QUALITATIV
E AND QUANTITATIVE COMPOSIT
ION
Tesavel 25 mg film-
coated tablets
Each tablet contains sitagliptin phosphate monohydrate, equivalent to
25
mg sitagliptin.
Tesavel 50 mg film-coated tablets
Each tablet contains sitagliptin phosphate monohydrate, equivalent
to 50
mg sitagliptin
.
Tesavel 100 mg film-
coated tablets
Each tablet contains sitagliptin phosphate monohydrate, equivalent to
100
mg sitagliptin
.
For the full list of
excipients, s
ee section 6.1.
3.
PHARMACEUTICAL
FORM
Film-
coated tablet
(tablet).
Tesavel 25 mg film-coated tablets
Rou
nd, pink film
-
coated tablet with “221” on one side.
Tesavel 50 mg film-
coated tablets
Round, light beige film
-
coated table
t with “112” on one side
.
Tesavel 100 mg film-
coated tablets
Round, beige f
ilm-
coated tablet wi
th “277” on one side.
4.
CLINICAL
PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For adult patients with type
2 diabetes mellitus,
Tesavel
is indicated to improve glycaemic control:
as monotherapy:
•
in patients inadequately controlled by diet and exercise
alone and for whom metformin is
inapp
ropriate due to contraindications or intolerance.
as dual oral
t
herapy in combination with
:
•
metformin when diet and exercise plus metformin alone d
o not provide adequate glycaemic
control.
•
a sulphonylurea when diet and
exercise plus
maximal tolerated do
se of a sulphonylurea alone do
not provide adequate glycaemic co
nt
rol and when metformin is inappropriate due to
contraindications or intolerance.
3
•
a
peroxisome proliferator
-
activated receptor gamma (
PPAR

)
agonist (i.e.
a thiazolidine
dione)
when use of a PPAR

agonist is appropriate and when diet and exercise plus the
PPAR

agonist
alone do not provide adequate glycaemic control.
as triple oral thera
py in combination with
:
•
a sulphonylurea and metformin when diet and ex
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 19-09-2023
Karakteristik produk Karakteristik produk Bulgar 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 20-12-2012
Selebaran informasi Selebaran informasi Spanyol 19-09-2023
Karakteristik produk Karakteristik produk Spanyol 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 20-12-2012
Selebaran informasi Selebaran informasi Cheska 19-09-2023
Karakteristik produk Karakteristik produk Cheska 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 20-12-2012
Selebaran informasi Selebaran informasi Dansk 19-09-2023
Karakteristik produk Karakteristik produk Dansk 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 20-12-2012
Selebaran informasi Selebaran informasi Jerman 19-09-2023
Karakteristik produk Karakteristik produk Jerman 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 20-12-2012
Selebaran informasi Selebaran informasi Esti 19-09-2023
Karakteristik produk Karakteristik produk Esti 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 20-12-2012
Selebaran informasi Selebaran informasi Yunani 19-09-2023
Karakteristik produk Karakteristik produk Yunani 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 20-12-2012
Selebaran informasi Selebaran informasi Prancis 19-09-2023
Karakteristik produk Karakteristik produk Prancis 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 20-12-2012
Selebaran informasi Selebaran informasi Italia 19-09-2023
Karakteristik produk Karakteristik produk Italia 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 20-12-2012
Selebaran informasi Selebaran informasi Latvi 19-09-2023
Karakteristik produk Karakteristik produk Latvi 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 20-12-2012
Selebaran informasi Selebaran informasi Lituavi 19-09-2023
Karakteristik produk Karakteristik produk Lituavi 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 20-12-2012
Selebaran informasi Selebaran informasi Hungaria 19-09-2023
Karakteristik produk Karakteristik produk Hungaria 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 20-12-2012
Selebaran informasi Selebaran informasi Malta 19-09-2023
Karakteristik produk Karakteristik produk Malta 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 20-12-2012
Selebaran informasi Selebaran informasi Belanda 19-09-2023
Karakteristik produk Karakteristik produk Belanda 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 20-12-2012
Selebaran informasi Selebaran informasi Polski 19-09-2023
Karakteristik produk Karakteristik produk Polski 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 20-12-2012
Selebaran informasi Selebaran informasi Portugis 19-09-2023
Karakteristik produk Karakteristik produk Portugis 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 20-12-2012
Selebaran informasi Selebaran informasi Rumania 19-09-2023
Karakteristik produk Karakteristik produk Rumania 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 20-12-2012
Selebaran informasi Selebaran informasi Slovak 19-09-2023
Karakteristik produk Karakteristik produk Slovak 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 20-12-2012
Selebaran informasi Selebaran informasi Sloven 19-09-2023
Karakteristik produk Karakteristik produk Sloven 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 20-12-2012
Selebaran informasi Selebaran informasi Suomi 19-09-2023
Karakteristik produk Karakteristik produk Suomi 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 20-12-2012
Selebaran informasi Selebaran informasi Swedia 19-09-2023
Karakteristik produk Karakteristik produk Swedia 19-09-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 20-12-2012
Selebaran informasi Selebaran informasi Norwegia 19-09-2023
Karakteristik produk Karakteristik produk Norwegia 19-09-2023
Selebaran informasi Selebaran informasi Islandia 19-09-2023
Karakteristik produk Karakteristik produk Islandia 19-09-2023
Selebaran informasi Selebaran informasi Kroasia 19-09-2023
Karakteristik produk Karakteristik produk Kroasia 19-09-2023

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen